Savara (NASDAQ:SVRA - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02), Zacks reports. The company had revenue of $0.27 million during the quarter.
Savara Price Performance
NASDAQ SVRA traded up $0.09 on Tuesday, reaching $2.86. 447,331 shares of the stock traded hands, compared to its average volume of 1,316,403. Savara has a 12 month low of $2.26 and a 12 month high of $5.34. The company has a market cap of $489.97 million, a price-to-earnings ratio of -6.66 and a beta of 0.60. The firm's fifty day simple moving average is $2.72 and its 200 day simple moving average is $3.24. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13.
Analyst Ratings Changes
A number of research firms have issued reports on SVRA. HC Wainwright reiterated a "buy" rating and issued a $6.00 target price on shares of Savara in a research note on Friday. JMP Securities restated a "market outperform" rating and issued a $9.00 target price on shares of Savara in a research report on Thursday, December 19th. Finally, Wells Fargo & Company began coverage on shares of Savara in a research note on Friday, December 20th. They issued an "overweight" rating and a $8.00 price target on the stock. One analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $8.83.
View Our Latest Research Report on Savara
Savara Company Profile
(
Get Free Report)
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Recommended Stories
Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
